Aventis/DuPont
Executive Summary
Talks discontinued regarding sale of Aventis' Romainville, France R&D facility to DuPont. The negotiation, which was initiated in March, would have included the sale of eight Aventis products and the transfer of a 300-person sales force to DuPont. Former DuPont Pharmaceuticals CEO Kurt Landgraf touted the agreement as a means for DuPont to benefit from consolidation without pursuing a merger of its own (1"The Pink Sheet" March 13, p. 19). Landgraf was replaced by Nicholas Teti in May. Aventis said it will seek a new buyer for the plant
You may also be interested in...
DuPont R&D Deal With Aventis Begins Strategy Of Merger Remnant Buying
DuPont plans to participate in the current wave of pharmaceutical industry mergers by acquiring pieces of merging companies that have been made redundant rather than by a direct acquisition of its own.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials